



(12) Translation of  
European patent specification

(11) NO/EP 3520786 B1

NORWAY

(19) NO

(51) Int Cl.

**A61K 31/19 (2006.01)**

**A61K 31/197 (2006.01)**

**A61K 31/403 (2006.01)**

**A61K 31/4439 (2006.01)**

**A61K 31/4985 (2006.01)**

**A61K 31/513 (2006.01)**

**A61K 31/5513 (2006.01)**

**A61P 3/10 (2006.01)**

**Norwegian Industrial Property Office**

---

|      |                                                                            |                                                                                                                                                                                                   |
|------|----------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (45) | Translation Published                                                      | 2023.10.16                                                                                                                                                                                        |
| (80) | Date of The European<br>Patent Office Publication of<br>the Granted Patent | 2023.08.09                                                                                                                                                                                        |
| (86) | European Application Nr.                                                   | 18182706.4                                                                                                                                                                                        |
| (86) | European Filing Date                                                       | 2018.07.10                                                                                                                                                                                        |
| (87) | The European Application's<br>Publication Date                             | 2019.08.07                                                                                                                                                                                        |
| (30) | Priority                                                                   | 2018.02.06, RU, 2018104548                                                                                                                                                                        |
| (84) | Designated Contracting<br>States:                                          | AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ;<br>IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ;<br>SK ; SM ; TR |
| (73) | Proprietor                                                                 | LEVICURE Ltd., Mania 10/7 b,, Rishon LeZiyon 7524166, Israel                                                                                                                                      |
| (72) | Inventor                                                                   | LEVIT, Shmuel Boris, 17 Hertzal, P.O. Box 195, 38101 Hadera, Israel                                                                                                                               |
| (74) | Agent or Attorney                                                          | PLOUGMANN VINGTOFT, C. J. Hambros plass 2, 0164 OSLO, Norge                                                                                                                                       |

---

(54) Title                    **A COMBINATION OF SUBSTANCES FOR USE IN REGENERATIVE THERAPY IN PATIENTS  
WITH TYPE 1 DIABETES MELLITUS**

(56) References  
Cited:                    WO-A2-2006/000567  
                              US-A1- 2014 322 213  
                              LIU WENJUAN ET AL: "Combined Oral Administration of GABA and DPP-4 Inhibitor Prevents  
Beta Cell Damage and Promotes Beta Cell Regeneration in Mice", FRONTIERS IN  
PHARMACOLOGY, vol. 8, 20 June 2017 (2017-06-20),

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

## Patentkrav

1. Oralt administrert kombinasjon for anvendelse i regenerativ terapi hos pasienter med diabetes mellitus type 1, nemlig for gjenvinning av  $\beta$ -cellene i bukspyttkjertelen, **karakterisert ved at** den består av: et medikament som tilhører gruppen av dipeptidylpeptidase-(DPP-4)-inhibitorer og inneholder en terapeutisk effektiv mengde av DPP-4-inhibitor, som utgjør opptil 25 til 100 mg/dag; et medikament av protonpumpeinhibitorgruppen (PPI) som inneholder en terapeutisk effektiv mengde av PPI, omfattende 10 til 40 mg/dag; og terapeutisk effektiv daglig dose av gamma-aminosmørsyrepreparat (GABA) eller gamma-aminosmørsyrereseptoragonist på 375 til 1500 mg/dag.
2. Kombinasjon for anvendelse ifølge krav 1, **karakterisert ved at** medikamentet i DPP-4-inhibitorgruppen er sitagliptin, hvori medikamentet i PPI-gruppen er omeprazol.